Patents by Inventor Richard J Simpson
Richard J Simpson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6387875Abstract: The present invention relates to a isolated leukaemia inhibitory factor (LIF)-binding protein (LBP) in soluble form and obtainable from a first mammalian species, said LBP capable of inhibiting the ability of LIF from a second mammalian species to induce differentiation of M1 myeloid leukaemic cells in vitro to a greater extent when compared to its ability to inhibit LIF from said first mammalian species.Type: GrantFiled: November 10, 1994Date of Patent: May 14, 2002Assignee: Amrad Corporation LimitedInventors: Nicos Anthony Nicola, Meredith Layton, Donald Metcalf, Richard J Simpson
-
Publication number: 20020023279Abstract: A transgenic plant cell is provided containing a DNA molecule encoding an enzyme selected from the group consisting of fructosyltransferase, glucosyltransferase B, mutants of glucosyltransferase B, glucosyltransferase C, glucosyltransferase D, mutants of glucosyltransferase D and functional fragments of each enzyme. A transgenic plant regenerated from the plant cell is also provided. A method of improving the ensilability and the nutritional value of plants is also provided comprising introducing into the cells of the plant an expression cassette comprising the above DNA molecule operably linked to a promoter functional in the cells of the plant to yield transformed plant cells, and regenerating a transformed plant from the transformed cells. The transformed plants also provide improved digestibility in ruminants.Type: ApplicationFiled: April 27, 2001Publication date: February 21, 2002Inventors: Francois J. Loiselle, Scott E. Nichols, Colin Leslie Dow Jenkins, Richard J. Simpson
-
Publication number: 20020019997Abstract: A transgenic plant cell is provided containing a DNA molecule encoding an enzyme selected from the group consisting of fructosyltransferase, glucosyltransferase B, mutants of glucosyltransferase B, glucosyltransferase C, glucosyltransferase D, mutants of glucosyltransferase D and functional fragments of each enzyme. A transgenic plant regenerated from the plant cell is also provided. A method of improving the ensilability and the nutritional value of plants is also provided comprising introducing into the cells of the plant an expression cassette comprising the above DNA molecule operably linked to a promoter functional in the cells of the plant to yield transformed plant cells, and regenerating a transformed plant from the transformed cells. The transformed plants also provide improved digestibility in ruminants.Type: ApplicationFiled: June 12, 2001Publication date: February 14, 2002Inventors: Francois J. Loiselle, Scott E. Nichols, Colin Leslie Dow Jenkins, Richard J. Simpson
-
Patent number: 6291235Abstract: This invention relates to isolated proteins and to peptides which are found on the surface of colon cells and colon cancer cells, as well as to nucleic acid molecules encoding said protein and peptides. The protein and peptides bind to tumor associated antibodies, such as mAb 33. The monomeric protein has a molecular weight of about 43 kD as determined by SDS gel electrophoresis under non-reducing conditions. In addition, this invention relates to the use of said nucleic acid molecules, protein, in monomeric or multimeric form, and to antibodies to said peptides in diagnostic, screening and therapeutic methods. This invention further relates to antibodies specific for said protein, in monomeric or multimeric form, and to antibodies to said peptides.Type: GrantFiled: December 10, 1998Date of Patent: September 18, 2001Assignee: Ludwig Institute for Cancer ResearchInventors: Sydney Welt, Sara White, Cameron Johnstone, Lloyd J Old, Gerd Ritter, Bruno Catimel, Hong Ji, Antony Burgess, Joan Heath, Richard J Simpson, Edouard Nice, R. L Moritz
-
Patent number: 6147201Abstract: Isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, DNA encoding two major D. farinae allergens, Der f I and Der f II and DNA encoding a D. pteronyssinus allergen, Der p I. In addition, the proteins or peptides encoded by the isolated DNA, their use as diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens.Type: GrantFiled: June 7, 1995Date of Patent: November 14, 2000Assignee: ImmuLogic Pharmaceutical CorporationInventors: Wayne Robert Thomas, Geoffrey A. Stewart, Keven J. Turner, Richard J. Simpson
-
Patent number: 5972352Abstract: Recombinant DNA expression vectors or cloning vehicles capable of expressing a polypeptide displaying the antigenicity of an allergen of house dust mites of the genus Dermatophagoides. A synthetic protein or polypeptide displaying the antigenicity of all or a portion of an allergen of house dust mites of the genus Dermatophagoides. Methods of diagnosing and treating such allergies.Type: GrantFiled: November 8, 1993Date of Patent: October 26, 1999Inventors: Wayne R. Thomas, Geoffrey A. Stewart, Keven J. Turner, Richard J. Simpson, Kaw-Yan Chua
-
Patent number: 5750377Abstract: The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports interleukin 2- and interleukin 4-independent growth of helper T cells especially from murine and human sources and further which is capable of augmenting proliferation of IL3- or IL4-responsive cells. Even more particularly, the present invention relates to the helper T cell growth factor P40, pharmaceutical compositions thereof, antibodies thereto and recombinant DNA clones thereof. The present invention also contemplates a method for inducing the proliferation of helper T cells as well as IL3- and Il4-responsive cells. The helper T cells growth factor contemplated herein is useful in the stimulation of specific cells in the immune system, either alone or in combination with IL3 or IL4.Type: GrantFiled: May 23, 1995Date of Patent: May 12, 1998Assignee: Ludwig Institute for Cancer ResearchInventors: Jacques Van Snick, Catherine Uyttenhove, Richard J. Simpson
-
Patent number: 5712369Abstract: This invention relates to isolated protein and to peptides which are found on the surface of colon cells and colon cancer cells, as well as to nucleic acid molecules encoding said protein and peptides. The protein and peptides bind to tumor-associated antibodies, such as mAb A33. The monomeric protein has a molecular weight of about 43 kD as determined by SDS gel electrophoresis under non-reducing conditions. In addition, this invention relates to the use of said nucleic acid molecules, protein, in monomeric or multimeric form, and to antibodies to said peptides in diagnostic, screening and therapeutic methods. This invention further relates to antibodies specific for said protein, in monomeric or multimeric form, and to antibodies to said peptides.Type: GrantFiled: February 2, 1996Date of Patent: January 27, 1998Assignee: Ludwig Institute for Cancer ResearchInventors: Lloyd J. Old, Sydney Welt, Gerd Ritter, Richard J. Simpson, Edouard Nice, R. L. Moritz, B. Catimel, Hong Ji, Anthony W. Burgess, Joan K. Heath, Sara J. White, Cameron Johnstone
-
Patent number: 5605839Abstract: This invention relates to methods and apparatus for carrying out chemical reactions between a plurality of reactants and in particular it is amenable to micro or nano scale operation and to the sequential chemical reactions required during such processes as construction or sequencing of proteins, oligonucleotides and polysaccharides. The present invention further relates to a capillary liquid chromatography system for high-sensitivity component separation and microsequencing for use in association with the methods and apparatus herein described.Type: GrantFiled: May 29, 1992Date of Patent: February 25, 1997Assignee: Ludwig Institute for Cancer ResearchInventors: Richard J. Simpson, Antony W. Burgess, Robert L. Moritz
-
Patent number: 5587302Abstract: The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports interleukin 2- and interleukin 4-independent growth of helper T cells especially from murine and human sources and further which is capable of augmenting proliferation of IL3- or IL4-responsive cells. Even more particularly, the present invention relates to the helper T cell growth factor P40, pharmaceutical compositions thereof, antibodies thereto and recombinant DNA clones thereof. The present invention also contemplates a method for inducing the proliferation of helper T cells as well as IL3- and Il4-responsive cells. The helper T cells growth factor contemplated herein is useful in the stimulation of specific cells in the immune system, either alone or in combination with IL3 or IL4.Type: GrantFiled: January 8, 1990Date of Patent: December 24, 1996Assignee: Ludwig Institute For Cancer ResearchInventors: Jacques Van Snick, Catherine Uyttenhove, Richard J. Simpson
-
Patent number: 5547940Abstract: The invention describes how known peptide POMC.sub.76-103 can be used to stimulate colon cell proliferation. The peptide can be used alone, or in combination with other cell proliferation stimulating agents.Type: GrantFiled: February 28, 1994Date of Patent: August 20, 1996Assignee: Ludwig Institute for Cancer ResearchInventors: Edouard C. Nice, Robert James, Richard J. Simpson, Antony W. Burgess, Robert H. Whitehead
-
Patent number: 5516698Abstract: A first reactant is immobilized i.e. in a porous matrix (50), adjacent a sample electrode (46) within a reaction chamber. Energizing of the electrode (46) electrophoretically attracts a mobile second reactant and/or electrolytically induces appropriate reaction conditions to enhance reaction of the first and second reactants. Polarity reversals between the sample electrode (46) and remote electrodes (38), (42), (44) cause unreacted second reactant and/or by-products to migrate away from the immobilized first reactant. The techniques are useful for sequential chemical reactions such as sequencing or construction of proteins, polysaccharides and nucleic acids where cyclical additions and removals of reactants are required. The techniques are amenable to automated micro and nano scale construction and operation and allow direct electrophoretic (38) interfacing with chromatographic, HPCE and mass spectrophotometric equipment.Type: GrantFiled: April 30, 1992Date of Patent: May 14, 1996Assignee: Ludwig Institute For Cancer ResearchInventors: Geoffrey S. Begg, Richard J. Simpson, Antony W. Burgess
-
Patent number: 5443825Abstract: Leukemia-inhibitory factor (LIF) has been produced in essentially pure form from murine or human sources. A method of purifying this LIF is disclosed, as well as polypeptides having LIF activity which are not identical in amino acid sequence to any naturally occurring form of LIF. The polypeptides can be used for hindering the proliferation of myeloid Leukemia cells.Type: GrantFiled: September 22, 1992Date of Patent: August 22, 1995Assignee: Amrad Corporation LimitedInventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
-
Patent number: 5427925Abstract: The present invention provides a method for producing recombinant leukemia inhibitory factor (LIF) by the expression, in suitable host cells, of recombinant DNA molecules encoding LIF.Type: GrantFiled: May 6, 1993Date of Patent: June 27, 1995Assignee: Amrad Corporation LimitedInventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
-
Patent number: 5208218Abstract: The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports interleukin 2- and interleukin 4-independent growth of helper T cells. Even more particularly, the present invention relates to the helper T cell growth factor P40, pharmaceutical compositions thereof and antibodies thereto. The present invention also contemplates a method for inducing the proliferation of helper T cells. The helper T cell growth factor contemplated herein is useful in the stimulation of specific cells in the immune system.Type: GrantFiled: September 19, 1988Date of Patent: May 4, 1993Assignee: Ludwig Institute for Cancer ResearchInventors: Jacques Van Snick, Catherine Uyttenhove, Richard J. Simpson
-
Patent number: 5187077Abstract: A leukaemia-inhibitory factor (LIF) is disclosed, together with a method of preparation of LIF in essentially pure form. Nucleotide and amino acid sequences are disclosed, together with recombinant DNA moleclues and host cells for production of polypeptides having LIF activity.Type: GrantFiled: December 9, 1988Date of Patent: February 16, 1993Assignee: Amrad Corporation LimitedInventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
-
Patent number: 5157112Abstract: The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports interleukin 2- and interleukin 4-independent growth of helper T cells especially from murine and human sources and further which is capable of augmenting proliferation of IL3- or IL4-responsive cells. Even more particularly, the present inventin relates to the helper T cell growth factor P40, pharmaceutical compositions thereof, antibodies thereto and recombinant DNA clones thereof. The present invention also contemplates a method for inducing the proliferation of helper T cells as well as IL3- and Il4-responsive cells. The helper T cells growth factor contemplated herein is useful in the stimulation of specific cells in the immune system, either alone or in combination with IL3 or IL4.Type: GrantFiled: September 15, 1989Date of Patent: October 20, 1992Assignee: Ludwig Institute for Cancer ResearchInventors: Jacques Van Snick, Catherine Uyttenhove, Richard J. Simpson